Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 88 peer-reviewed journal articles Updated
Breast Surgery · Ductal Carcinoma In Situ

Ductal Carcinoma In Situ (DCIS): A Patient Guide

At a Glance

DCIS is Stage 0 breast cancer confined to the milk ducts, so it has not invaded nearby tissue or lymph nodes. It can become invasive but may not, so patients and care teams weigh lumpectomy, radiation, mastectomy, or monitored clinical-trial options.

A diagnosis of Ductal Carcinoma In Situ (DCIS) often brings a confusing mix of relief and urgency. While it is officially classified as Stage 0 breast cancer, DCIS is fundamentally different from invasive disease because the abnormal cells are strictly contained within the milk ducts [1]. This means the cells have not broken through the protective basement membrane to reach the surrounding breast tissue or lymph nodes [2]. For this reason, the long-term, population-level breast-cancer-specific survival rate for those diagnosed with DCIS is near 100%, making it a condition that is highly treatable [3].

Despite this excellent prognosis, DCIS presents a unique clinical paradox: it is a “non-obligate precursor,” meaning while it has the potential to become invasive cancer if left alone, it is not guaranteed to do so [4]. Because doctors cannot yet perfectly predict which cases will progress, the standard approach is to treat the area to prevent a future invasive recurrence [5]. This shift toward prevention means that your journey will involve weighing the benefits of surgery and radiation against the potential for overtreatment, focusing on maintaining your health while minimizing unnecessary side effects [6]. Treatment does not perfectly eliminate the risk of an ipsilateral recurrence or a new cancer in the other breast, which is why long-term follow-up is necessary.

Managing DCIS is a collaborative process that centers on tailoring treatment to your specific risk profile. Most patients choose between breast-conserving surgery (lumpectomy) often followed by radiation, or a mastectomy for more extensive cases [7]. Newer options, such as active surveillance within structured clinical trials, are also emerging for those with low-risk features who wish to monitor the condition closely rather than having immediate surgery [8]. Ultimately, your care team will help you navigate these paths, ensuring you have the information needed to move forward with a plan that protects your future while respecting your quality of life [9].

In this guide

6 chapters

01

Understanding Your DCIS Diagnosis

Learn what a DCIS diagnosis means, why it is called Stage 0 breast cancer, how it differs from invasive cancer, and how doctors weigh treatment choices.

02

Decoding Your Pathology Report

Learn how to read a ductal carcinoma in situ (DCIS) pathology report, including margins, nuclear grade, necrosis, microinvasion, ER status, and treatment.

03

Surgery and Radiation: Managing the Risk

Learn how lumpectomy, mastectomy, radiation, and sentinel node biopsy affect recurrence risk, side effects, and treatment decisions for DCIS after surgery.

04

Choosing Less: Medication and Active Monitoring

Learn how DCIS endocrine therapy and active surveillance work, who may qualify, medication risks, and how hidden invasive cancer affects surgery decisions.

05

Calculating Your Risk: Scoring Tools and Factors

Learn how DCIS risk scores estimate recurrence, including the Van Nuys index, Oncotype DX DCIS Score, age, margins, tumor size, and factors guiding treatment.

06

Survivorship: Your Life After Treatment

Learn about ductal carcinoma in situ (DCIS) survivorship, including mammograms, recurrence risk, endocrine therapy side effects, bone health, and scan anxiety.

Common questions in this guide

What is DCIS, and is it invasive breast cancer?
DCIS is a group of abnormal cells confined to the milk ducts of the breast. It is classified as Stage 0 breast cancer because the cells have not invaded surrounding breast tissue or lymph nodes, but it can sometimes become invasive if it is not treated.
Can DCIS turn into invasive breast cancer?
DCIS can progress to invasive breast cancer, but it is not guaranteed to do so. Because doctors cannot yet predict every case that will progress, treatment or carefully monitored options may be discussed based on the individual situation.
What treatments are available for DCIS?
Common treatment choices include breast-conserving surgery, also called a lumpectomy, often followed by radiation, or a mastectomy when the area is more extensive. Active surveillance in a structured clinical trial may be considered for some people with low-risk DCIS.
Can I monitor low-risk DCIS instead of having surgery?
Active surveillance is an emerging approach being studied for selected people with low-risk DCIS, usually through structured clinical trials. Ask your care team whether you qualify and how monitoring would address the possibility of future invasive disease.
What does an upgrade from DCIS to invasive cancer mean?
An upgrade means that examination of the complete tissue sample finds invasive cancer that was not identified in the original sample. Your care team can explain how likely this is based on your pathology and whether it would change your treatment plan.

Get notified when new evidence is published on ductal breast carcinoma in situ.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (9)
  1. 1

    Advancements in Detection and Management of Ductal Carcinoma in Situ.

    Tucunduva TCM, Zanetta VC, Chala LF, et al.

    Radiographics : a review publication of the Radiological Society of North America, Inc 2025; (45(9)):e240174 doi:10.1148/rg.240174.

    PMID: 40773373
  2. 2

    Myoepithelial cell differentiation markers in ductal carcinoma in situ progression.

    Russell TD, Jindal S, Agunbiade S, et al.

    The American journal of pathology 2015; (185(11)):3076-89.

    PMID: 26343330
  3. 3

    Clinical outcomes of patients with ductal carcinoma in situ in Hong Kong: 10-year territory-wide cancer registry study.

    Co M, Ngan RKC, Mang OWK, et al.

    Hong Kong medical journal = Xianggang yi xue za zhi 2020; (26(6)):486-491 doi:10.12809/hkmj198203.

    PMID: 33277445
  4. 4

    Ductal carcinoma in situ current trends, controversies, and review of literature.

    Hong YK, McMasters KM, Egger ME, Ajkay N

    American journal of surgery 2018; (216(5)):998-1003 doi:10.1016/j.amjsurg.2018.06.013.

    PMID: 30244816
  5. 5

    Adjuvant therapy in patients with ductal carcinoma in situ of the breast: The Pandora's box.

    Lazzeroni M, Dunn BK, Pruneri G, et al.

    Cancer treatment reviews 2017; (55()):1-9 doi:10.1016/j.ctrv.2017.01.010.

    PMID: 28262606
  6. 6

    Ductal Carcinoma in Situ: State-of-the-Art Review.

    Grimm LJ, Rahbar H, Abdelmalak M, et al.

    Radiology 2022; (302(2)):246-255 doi:10.1148/radiol.211839.

    PMID: 34931856
  7. 7

    Local Relapse After Breast-Conserving Therapy Versus Mastectomy for Extensive Pure Ductal Carcinoma In Situ ≥4 cm.

    Hamilton SN, Nichol A, Wai E, et al.

    International journal of radiation oncology, biology, physics 2019; (103(2)):381-388 doi:10.1016/j.ijrobp.2018.09.022.

    PMID: 30253237
  8. 8

    The COMET (Comparison of Operative versus Monitoring and Endocrine Therapy) trial: a phase III randomised controlled clinical trial for low-risk ductal carcinoma in situ (DCIS).

    Hwang ES, Hyslop T, Lynch T, et al.

    BMJ open 2019; (9(3)):e026797 doi:10.1136/bmjopen-2018-026797.

    PMID: 30862637
  9. 9

    Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology.

    Gradishar WJ, Anderson BO, Balassanian R, et al.

    Journal of the National Comprehensive Cancer Network : JNCCN 2018; (16(3)):310-320 doi:10.6004/jnccn.2018.0012.

    PMID: 29523670

This page is for informational purposes only and does not constitute medical advice about DCIS. Discuss your pathology, treatment options, and follow-up plan with your breast care team.